Skip to main content
. 2020 Jan 28;14:3. doi: 10.3389/fncel.2020.00003

Figure 7.

Figure 7

Percent decrease in the length of perfused capillaries after 60 min of CBFR in the different experimental groups: SO-S, H, Tiv (10 mg/kg b.w. of Taurisolo® administered i.v. prior to CBFD and at the beginning of CBFR), Tor (20 mg/kg b.w. of Taurisolo® orally administered for 1 month and subjected to CBFD and CBFR), L-Tiv (L-NIO 10 mg/kg i.v. prior to i.v. Taurisolo® i.v.) and L-Tor (L-NIO 10 mg/kg i.v. prior to oral Taurisolo®) subgroups, treated before CBFD and at the beginning of CBFR. °p < 0.01 vs. baseline, *p < 0.01 vs. SO-S subgroup and ∧p < 0.01 vs. H group.